Review

histamine release buffer hrb (Immunotec inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Immunotec inc histamine release buffer hrb
Histamine Release Buffer Hrb, supplied by Immunotec inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/histamine+release+buffer+(hrb)/histamine+release+buffer+hrb/pmc06900099-66-14-18
Average 90 stars, based on 1 article reviews

histamine release buffer hrb - by Bioz Stars, 2026-09

90/100 stars

Images

Sedimentation:

Article Title: Expression of a major plant allergen as membrane-anchored and secreted protein in human cells with preserved T cell and B cell epitopes.
Article Snippet: Background: Expression of allergens in human cells is a prerequisite for the development of antigen-specific cell therapy in IgE-mediated allergy.. We developed a strategy how the clinically relevant major grass pollen allergen Phl p 5 can be efficiently secreted or expressed on the surface of human cells with preserved allergenic activity.. Methods: The cDNA of Phl p 5 was fused to a leader peptide with or without a transmembrane domain and both constructs were ligated into a mammalian expression vector.

other:

Article Title: Mixed-lineage eosinophil/basophil crisis in MDS: a rare form of progression.
Article Snippet: Background Basophilic crisis and eosinophilia are well recognized features of advanced chronic myeloid leukaemia.. In other myeloid neoplasms, however, transformation with marked basophilia and eosinophilia is considered unusual.. Design We examined the long-term follow-up of 322 patients with de novo myelodysplastic syndromes (MDS) to define the frequency of basophilic, eosinophilic and mixed lineage (basophilic and eosinophilic) transformation.

Incubation:

Article Title: Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells
Article Snippet: .. After incubation, cells were washed in phosphate‐buffered saline (PBS, Gibco Life Technologies), resuspended in histamine release buffer (HRB, Immunotech, Marseille, France) and then incubated with 5 μg/mL goat anti‐dog‐IgE antibody (Bethyl Laboratories) at 37°C for 30 minutes. .. After incubation, cells were centrifuged at 4°C, and the cell‐free supernatants and cell pellets were recovered and analysed for histamine content by radioimmunoassay (RIA, Immunotech).

Saline:

Image Search Results

Effects of ibrutinib on IgE‐mediated histamine release in human basophils. Basophils ( BA ) obtained from three nonallergic donors (A) or patients allergic to Der p 2 (n=3) or Phl p 5 (n=3) (B) were preincubated in control medium (Co) or various concentrations of ibrutinib (0.001‐1 μmol/L) at 37°C for 30 minutes. Then, cells were exposed to anti‐IgE (1 μg/mL; nonallergic donors) or recombinant allergens (1 μg/mL of rDer p 2 or rPhl p 5; allergic patients) at 37°C for 30 minutes. After centrifugation, histamine concentrations were determined in supernatants and cell lysates. Histamine release is expressed as percentage of total histamine. Results show the percentage of control and represent mean± SD of three independent experiments. Asterisk (*): P <0.05 by Student's t test. (C) BA from two patients allergic to Der p 2 (left and right panel) were incubated in control medium (Co) or 1 μmol/L ibrutinib at 37°C for 30 minutes. Then, cells were incubated in histamine release buffer ( HRB ) in the absence or presence of rDer p 2 (0.001‐10 μg/mL) at 37°C for 30 minutes. After incubation, cells were centrifuged at 4°C and cell‐free supernatants and cell suspensions analyzed for histamine content. Histamine release is expressed as percentage of total histamine. Results represent the mean± SD of triplicates. (D) Left panel: BA from a patient with chronic lymphocytic leukemia ( CLL ) were incubated in control medium (Co) or 1 μmol/L ibrutinib at 37°C for 30 minutes. Thereafter, cells were incubated in HRB in the absence or presence of anti‐IgE (0.001‐10 μg/mL) at 37°C for 30 minutes. After incubation, cells were centrifuged at 4°C and cell‐free supernatants and cell suspensions analyzed for histamine content. Histamine release is expressed as percentage of total histamine. Results represent the mean± SD of triplicates. Right panel: In the same patient with CLL , BA were obtained before therapy with ibrutinib (pretreatment; ■‐■) and 14 days after treatment with 280 mg/day ibrutinib (post‐treatment; ●‐●). Cells were incubated in HRB in the absence or presence of anti‐IgE antibody E‐124.2.8 (0.001‐10 μg/mL) for 30 minutes. Then, histamine release was measured as described above. Histamine release is expressed as percentage of total histamine. Results represent the mean± SD of triplicates.

Journal: Allergy

Article Title: BTK inhibition is a potent approach to block IgE‐mediated histamine release in human basophils

doi: 10.1111/all.13166

Figure Lengend Snippet: Effects of ibrutinib on IgE‐mediated histamine release in human basophils. Basophils ( BA ) obtained from three nonallergic donors (A) or patients allergic to Der p 2 (n=3) or Phl p 5 (n=3) (B) were preincubated in control medium (Co) or various concentrations of ibrutinib (0.001‐1 μmol/L) at 37°C for 30 minutes. Then, cells were exposed to anti‐IgE (1 μg/mL; nonallergic donors) or recombinant allergens (1 μg/mL of rDer p 2 or rPhl p 5; allergic patients) at 37°C for 30 minutes. After centrifugation, histamine concentrations were determined in supernatants and cell lysates. Histamine release is expressed as percentage of total histamine. Results show the percentage of control and represent mean± SD of three independent experiments. Asterisk (*): P <0.05 by Student's t test. (C) BA from two patients allergic to Der p 2 (left and right panel) were incubated in control medium (Co) or 1 μmol/L ibrutinib at 37°C for 30 minutes. Then, cells were incubated in histamine release buffer ( HRB ) in the absence or presence of rDer p 2 (0.001‐10 μg/mL) at 37°C for 30 minutes. After incubation, cells were centrifuged at 4°C and cell‐free supernatants and cell suspensions analyzed for histamine content. Histamine release is expressed as percentage of total histamine. Results represent the mean± SD of triplicates. (D) Left panel: BA from a patient with chronic lymphocytic leukemia ( CLL ) were incubated in control medium (Co) or 1 μmol/L ibrutinib at 37°C for 30 minutes. Thereafter, cells were incubated in HRB in the absence or presence of anti‐IgE (0.001‐10 μg/mL) at 37°C for 30 minutes. After incubation, cells were centrifuged at 4°C and cell‐free supernatants and cell suspensions analyzed for histamine content. Histamine release is expressed as percentage of total histamine. Results represent the mean± SD of triplicates. Right panel: In the same patient with CLL , BA were obtained before therapy with ibrutinib (pretreatment; ■‐■) and 14 days after treatment with 280 mg/day ibrutinib (post‐treatment; ●‐●). Cells were incubated in HRB in the absence or presence of anti‐IgE antibody E‐124.2.8 (0.001‐10 μg/mL) for 30 minutes. Then, histamine release was measured as described above. Histamine release is expressed as percentage of total histamine. Results represent the mean± SD of triplicates.

Article Snippet: Histamine release buffer (HRB) and histamine radioimmunoassay (RIA) kit were purchased from Immunotech, and RPMI 1640 medium, Iscove's modified Dulbecco's medium (IMDM), and fetal calf serum (FCS) from Thermo Fisher Scientific (Waltham, MA, USA).

Techniques: Control, Recombinant, Centrifugation, Incubation